161 related articles for article (PubMed ID: 32515087)
21. Biological agents in kidney transplantation: belatacept is entering the field.
Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
Expert Opin Biol Ther; 2010 Oct; 10(10):1501-8. PubMed ID: 20726688
[TBL] [Abstract][Full Text] [Related]
22. Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion.
Lo DJ; Anderson DJ; Weaver TA; Leopardi F; Song M; Farris AB; Strobert EA; Jenkins J; Turgeon NA; Mehta AK; Larsen CP; Kirk AD
Am J Transplant; 2013 Feb; 13(2):320-8. PubMed ID: 23311611
[TBL] [Abstract][Full Text] [Related]
23. Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients.
Kirk AD; Adams AB; Durrbach A; Ford ML; Hildeman DA; Larsen CP; Vincenti F; Wojciechowski D; Woodle ES
Am J Transplant; 2021 May; 21(5):1691-1698. PubMed ID: 33128812
[TBL] [Abstract][Full Text] [Related]
24. Corticosteroids and methotrexate as adjuvants to costimulation blockade in non-human primate renal transplantation.
Anderson DJ; Lo DJ; Leopardi F; Song M; Strobert EA; Jenkins JB; Larsen CP; Kirk AD
Clin Transplant; 2019 Jun; 33(6):e13568. PubMed ID: 31006146
[TBL] [Abstract][Full Text] [Related]
25. Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR).
Leibler C; Matignon M; Moktefi A; Samson C; Zarour A; Malard S; Boutin E; Pilon C; Salomon L; Natella PA; Durrbach A; Robert T; Canoui-Poitrine F; Grimbert P
Am J Transplant; 2019 Mar; 19(3):894-906. PubMed ID: 30582270
[TBL] [Abstract][Full Text] [Related]
26. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
[TBL] [Abstract][Full Text] [Related]
27. Steroid-free maintenance immunosuppression using alemtuzumab in pediatric kidney transplantation: Long-term longitudinal follow-up.
Jain A; Daoud D; Kees-Folts D; Freeman MA; Butt F; Abendroth CS; Shike H; Kadry Z
Pediatr Transplant; 2022 Mar; 26(2):e14173. PubMed ID: 34687570
[TBL] [Abstract][Full Text] [Related]
28. Differential effects of Belatacept on virus-specific memory versus de novo allo-specific T cell responses of kidney transplant recipients and healthy donors.
Kühne JF; Neudörfl C; Beushausen K; Keil J; Malysheva S; Wandrer F; Haller H; Messerle M; Blume C; Neuenhahn M; Schlott F; Hammerschmidt W; Zeidler R; Falk CS
Transpl Immunol; 2020 Aug; 61():101291. PubMed ID: 32330566
[TBL] [Abstract][Full Text] [Related]
29. Every 2-month belatacept maintenance therapy in kidney transplant recipients greater than 1-year posttransplant: A randomized, noninferiority trial.
Badell IR; Parsons RF; Karadkhele G; Cristea O; Mead S; Thomas S; Robertson JM; Kim GS; Hanfelt JJ; Pastan SO; Larsen CP
Am J Transplant; 2021 Sep; 21(9):3066-3076. PubMed ID: 33583120
[TBL] [Abstract][Full Text] [Related]
30. Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly.
Vincenti F; Blancho G; Durrbach A; Grannas G; Grinyó J; Meier-Kriesche HU; Polinsky M; Yang L; Larsen CP
Am J Transplant; 2017 Dec; 17(12):3219-3227. PubMed ID: 28758341
[TBL] [Abstract][Full Text] [Related]
31. Conversion to belatacept maintenance immunosuppression in HIV-positive kidney transplant recipients.
Santeusanio A; Bhansali A; De Boccardo G; Sehgal V; Delaney V; Florman S; Shapiro R
Clin Transplant; 2020 Oct; 34(10):e14041. PubMed ID: 32654239
[TBL] [Abstract][Full Text] [Related]
32. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors.
Le Meur Y; Aulagnon F; Bertrand D; Heng AE; Lavaud S; Caillard S; Longuet H; Sberro-Soussan R; Doucet L; Grall A; Legendre C
Am J Transplant; 2016 Jul; 16(7):2181-6. PubMed ID: 26718625
[TBL] [Abstract][Full Text] [Related]
33. CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept.
Karadkhele G; Hogan J; Magua W; Zhang W; Badell IR; Mehta A; Lyon M; Pastan S; Pearson TC; Larsen CP
Am J Transplant; 2021 Jan; 21(1):208-221. PubMed ID: 32519434
[TBL] [Abstract][Full Text] [Related]
34. B cell reconstitution following alemtuzumab induction under a belatacept-based maintenance regimen.
Xu H; Mehta AK; Gao Q; Lee HJ; Ghali A; Guasch A; Kirk AD
Am J Transplant; 2020 Mar; 20(3):653-662. PubMed ID: 31596034
[TBL] [Abstract][Full Text] [Related]
35. Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy.
Lowe MC; Badell IR; Turner AP; Thompson PW; Leopardi FV; Strobert EA; Larsen CP; Kirk AD
Am J Transplant; 2013 Feb; 13(2):312-9. PubMed ID: 23279640
[TBL] [Abstract][Full Text] [Related]
36. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring.
Knechtle SJ; Pascual J; Bloom DD; Torrealba JR; Jankowska-Gan E; Burlingham WJ; Kwun J; Colvin RB; Seyfert-Margolis V; Bourcier K; Sollinger HW
Am J Transplant; 2009 May; 9(5):1087-98. PubMed ID: 19344431
[TBL] [Abstract][Full Text] [Related]
37. Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study.
Sutherland AI; Akhtar MZ; Zilvetti M; Brockmann J; Ruse S; Fuggle SV; Sinha S; Harden P; Friend PJ
Am J Transplant; 2014 Mar; 14(3):677-84. PubMed ID: 24612687
[TBL] [Abstract][Full Text] [Related]
38. Belatacept Rescue Therapy in Kidney Transplant Recipients With Vascular Lesions: A Case Control Study.
Bertrand D; Cheddani L; Etienne I; François A; Hanoy M; Laurent C; Lebourg L; Le Roy F; Lelandais L; Loron MC; Godin M; Guerrot D
Am J Transplant; 2017 Nov; 17(11):2937-2944. PubMed ID: 28707779
[TBL] [Abstract][Full Text] [Related]
39. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients.
Ferguson R; Grinyó J; Vincenti F; Kaufman DB; Woodle ES; Marder BA; Citterio F; Marks WH; Agarwal M; Wu D; Dong Y; Garg P
Am J Transplant; 2011 Jan; 11(1):66-76. PubMed ID: 21114656
[TBL] [Abstract][Full Text] [Related]
40. Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients.
Wojciechowski D; Chandran S; Vincenti F
Clin Transplant; 2017 May; 31(5):. PubMed ID: 28190259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
